Foundation Medicine and Natera Announce the Launch of FoundationOne
https://www.natera.com/company/news/foundation-medicine-and-natera-announce-the-launch-of-foundationonetracker-personalized-circulating-tumor-dna-monitoring-assay-for-investigational-use-and-early-access-clinical-use/
WEBCambridge, Mass. , & Austin, Texas, January 9, 2023 – Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, and Natera, Inc., a global leader in cell-free DNA testing, today launched an early access program for clinical use of FoundationOne®Tracker, a personalized circulating tumor DNA (ctDNA) monitoring assay.
DA: 45 PA: 2 MOZ Rank: 22